Transforming cannabis plant
for medical purposes

Cannprisma-pharma is a 100% Portuguese company founded in 2018, which is dedicated to growing, processing, and transforming the cannabis plant for medical purposes. Cannprisma develops its activity along the entire value chain, with a Seed-to-sale structure that provides solutions for Growers, pharmaceutical wholesalers, pharmaceutical manufacturers and for Researchers.

Vision
To be a worldwide reference in the Medical Cannabis industry for our Ethics, Quality, Innovation and Safety inherent to the solutions we provide for the pharmaceutical industry.

Mission
Changing the “prism” from which society looks to Cannabis, through our products and services. To mitigate stigma and show to the public the benefits of using cannabis-based medicines as a treatment for specific medical conditions, and in symptoms management and relief.
Making available to the market products and raw materials that contribute to improving the welfare of patients around the world, respecting the highest standards of quality, safety, environmental sustainability, and social responsibility.

Our Values

Cannprisma spirit is based on health, transparency, and rigor. Our values include Ethics, Social and Environmental Responsibility, Safety, Quality, and Innovation.

Ethics
The Cannprisma code of ethical conduct is the foundation of any activity carried out by our employees.

Health
Is fundamental to us. We understand the needs of all those who can benefit from the use of cannabis-based medicines due to their health condition. Therefore, all the raw materials and products we develop aim to serve as tools to improve the well-being and quality of life of patients worldwide. Our goal is to dignify and facilitate access to the use of cannabis-based medicines.

Innovation
Within our team of young minds and open spirits, the desire to innovate to continuously improve our procedures, raw materials, products, and services is present. This is achieved through research projects and the establishment of institutional partnerships.

Environmental Sustainability
Taking care of people while simultaneously caring for the planet is one of Cannprisma’s main focuses. We invest in renewable energies to enhance our activities and incorporate mechanical processes into our cultivation, production, and transformation to give back to nature what it provides us.

Transparency
Our team performs their functions with maximum transparency. Beyond business relationships, we establish relationships of trust with our partners.

Safety
The Cannprisma entity operates under a meticulous security policy, covering our facilities, products, provided services, and activities.

Quality & Rigor
This is a mandatory factor in our raw materials, work methodologies, designed products, and provided services.
This is an indispensable pillar of our activity within the medicinal cannabis industry. Ensuring scientific rigor at all stages of the process is essential to ensure that the final product or provided service is worthy of its intended purpose in the pharmaceutical industry.

Social Responsibility
The purpose of our products and products conceived through the services we provide is of great importance and tremendous responsibility. That’s why our team is vertically concerned, aware, and socially responsible, as we recognize that the activities we carry out in the industry play a crucial role in the quality, safety, and effectiveness of cannabis-based medicines available to patients worldwide.

Our Team

We have an experienced and multidisciplinary team, which works with the commitment to do their best to make high quality products, services, and raw materials available to the market with the aim of improving the health and welfare of patients around the world. Get to know some of the forces that move us.

João Nascimento

João Nascimento

CEO & Founder

Paulo Nascimento

Paulo Nascimento

Executive Partner

Elsa Nascimento

Elsa Nascimento

Executive Partner

Fernando Águas

Fernando Águas

Qualified Person & Industrial Director

Rui Soares

Rui Soares

VP of International Sales & Marketing

José Real

José Real

Marketing Manager & Product Developer

Rui Dias

Rui Dias

U-GMP Post-Harvest Manager

Marcelo Melo

Marcelo Melo

Head of R&D & Extraction Unit

Zaida Giná

Zaida Giná

Quality Assurance Director

Maura Ferreira

Maura Ferreira

Quality Control Manager

Our Process

Cannabis flower production
from cultivation to delivering

Our Facilities

Cannprisma, with its Seed-to-sale structure, bridges two different sectors, the agricultural sector related to the cultivation of Cannabis and the pharmaceutical sector inherent to the processing and transformation of the plant.
To better respond to the needs of the industry, the company’s operations take place in two different units, the cultivation unit and the industrial unit.

Cannprisma Cultivation Unit

Cultivation Unit

Located in the south of Portugal in the Algarve, Castro Marim, it is in this GACP and CUMCS certified facility that we grow high-quality cannabis for medical use. Our facilities cover 60,000m2 of which 8,500m2 is cultivation area. In the cultivation unit we have high-tech greenhouses, processing unit, storage unit and research and development rooms.

Cannprisma - Factory

Industrial Unit

Located in the south of Portugal in the Algarve, Vila Real de Santo António, it is in this industrial unit with EU-GMP part I and part II certification that we process and transform the flower. Our factory has about 6000m2 and is equipped with a processing unit, a quality control laboratory, and an extraction unit.

Our Journey
  • Cannprisma Establishment

    October 2018

  • Start of the Manufacturing
    Unit construction

    December 2020

  • Obtaining the License to Grow
    Cannabis for Medical Purposes (GACP)

    August 2021

  • Inauguration of the Cultivation Unit

    September 2021

  • CUMCS Certification

    November 2021

  • Start of the Cultivation Unit Expansion

    June 2022

  • License to Manufacture Cannabis Medicines, Preparations and Substances for Medicinal Purposes (EU-GMP Part I)

    February 2023

  • License to Manufacture Active
    Substances (EU-GMP Part II)

    February 2023

  • Certification of the Quality Control Laboratories

    July 2024

  • License for Wholesale Distribution (GDP)

    2024

Cannprisma Products

Medical Cannabis Solutions

News & State of Art

Follow the company and industry.

Stay up to date with news from the company and the medical cannabis industry, subscribe to our newsletter and follow what we do for the industry, patients, and science!